Boehringer Ingelheim has achieved a significant milestone in the treatment of interstitial lung diseases with the approval of Jascayd (nerandomilast)…
Read More

Boehringer Ingelheim has achieved a significant milestone in the treatment of interstitial lung diseases with the approval of Jascayd (nerandomilast)…
Read More